INT89580

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 14.88
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (STAR) transport (STAR) mitochondrion (STAR)
small molecule metabolic process (STAR)
Anatomy Link Frequency
endothelium 1
STAR (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 3 80.52 Quite High
ischemia 10 74.16 Quite High
Inflammation 50 65.60 Quite High
rheumatoid arthritis 27 62.60 Quite High
agonist 3 51.12 Quite High
Angina 5 50.00 Quite Low
Pain 6 45.84 Quite Low
headache 6 40.28 Quite Low
Restless leg syndrome 6 39.52 Quite Low
methotrexate 6 17.96 Low Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 349 100.00 Very High Very High Very High
Cancer 35 99.40 Very High Very High Very High
Nicotine Addiction 86 99.14 Very High Very High Very High
Increased Venous Pressure Under Development 262 98.16 Very High Very High Very High
Adrenal Cancer 137 98.00 Very High Very High Very High
Reprotox - General 3 5 98.00 Very High Very High Very High
Reprotox - General 1 14 97.48 Very High Very High Very High
Heart Disease 11 95.36 Very High Very High Very High
Atherosclerotic Plaque 1 95.12 Very High Very High Very High
Peripheral Arterial Disease 16 94.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Partial loss of function missense mutations in the steroidogenic acute regulatory protein (StAR) gene has been associated with nonclassic lipoid adrenal hyperplasia; mutations in the ACTH receptor (MC2R) gene or the melanocortin 2 receptor accessory protein (MRAP) gene are associated with phenotypes similar to nonclassic lipoid adrenal hyperplasia [7].
Negative_regulation (loss) of StAR associated with adrenal cancer
1) Confidence 0.35 Published 2010 Journal International Journal of Pediatric Endocrinology Section Body Doc Link PMC2910408 Disease Relevance 0.75 Pain Relevance 0
Subjects demonstrated a significant increase in HDL-cholesterol from baseline to week 4 and week 8 and a decrease in total cholesterol/HDL ratio from baseline to week 4 (Table 3).
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
2) Confidence 0.04 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2831093 Disease Relevance 1.03 Pain Relevance 0
Further, subjects demonstrated an 8% increase in high density lipoprotein (HDL)-cholesterol and a 13% decrease in total cholesterol/HDL-cholesterol from baseline to week 4.
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
3) Confidence 0.04 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Abstract Doc Link PMC2831093 Disease Relevance 0.94 Pain Relevance 0
The effects of hydrogen rich water on the lipid profile in subjects who were current smokers demonstrated that there was a significant decrease in the total cholesterol/HDL ratio from baseline to week 4 (data not shown) and a significant increase in HDL from baseline to week 4 (p<0.05).
Negative_regulation (decrease) of cholesterol associated with nicotine addiction and disorder of lipid metabolism
4) Confidence 0.03 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2831093 Disease Relevance 1.41 Pain Relevance 0
There was a statistically significant and a clinically important decrease in total cholesterol/HDL ratio from baseline to week 4 and a statistically significant increase in HDL from baseline to week 4.
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
5) Confidence 0.03 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2831093 Disease Relevance 1.02 Pain Relevance 0
Results of the current study demonstrated a significant increase in HDL-cholesterol leading to a significant decrease in total cholesterol/HDL ratio by week 4.
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
6) Confidence 0.03 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2831093 Disease Relevance 1.16 Pain Relevance 0
Similar observations were also made in the Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) study, in which the addition of ERN on an ongoing statin treatment slowed the progression of atherosclerosis at 12 and 24 months.31,32 Most recently, this benefit was further demonstrated in ARBITER-6, in which niacin had a favorable impact on carotid itima-media thickness progression compared with ezetimibe in statin-treated patients.35 In addition to coronary stenosis regression, the HDL-C Atherosclerosis Treatment Study (HATS)33 showed that, compared to placebo, simvastatin plus niacin therapy significantly reduced cardiovascular events including coronary death, stroke, revascularization, myocardial infarction and worsening ischemia.
Negative_regulation (reducing) of cholesterol associated with coronary stenosis, stroke, ischemia, increased venous pressure under development, myocardial infarction, death and disorder of lipid metabolism
7) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857616 Disease Relevance 1.03 Pain Relevance 0.04
Among lipid-altering therapies, lowering LDL-C cholesterol with statins remains the most commonly used strategy in clinical practice.4–6 It has been shown to decrease the incidence of major cardiovascular events by 25% to 35%.
Negative_regulation (lowering) of cholesterol
8) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857616 Disease Relevance 0.67 Pain Relevance 0
It has been shown to be efficacious for the reduction of cardiovascular events in clinical trials.14–21 At therapeutic doses of 1500 to 2000 mg/day, niacin is efficacious for reducing LDL-C, TG and non-HDL-C cholesterol, while increasing HDL-C.22 Accordingly, niacin has the most potent HDL-C raising therapy among currently used lipid-modifying therapies.
Negative_regulation (reducing) of cholesterol associated with disorder of lipid metabolism
9) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857616 Disease Relevance 0.70 Pain Relevance 0
In an early phase III pivotal trial, LERN (40 mg of laropiprant/2000 mg of niacin) significantly improved lipid parameters compared to placebo, and resulted in 18.4% reduction in LDL-C, 20% increase in HDL-C, 25.8% reduction in TG, 19.8% decrease in non-HDL-C cholesterol, 18.8% decrease in ApoB and 6.9% increase in ApoA-1.41 In this study, two-thirds of patients were on a statin at enrollment and were randomized to LERN, ERN or placebo.
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
10) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857616 Disease Relevance 0.34 Pain Relevance 0
Male subjects demonstrated a significant increase in HDL-cholesterol from baseline to week 4 and week 8 and significant decrease in total cholesterol/HDL ratio from baseline to week 4 (p<0.05) (Table 3).
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
11) Confidence 0.01 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2831093 Disease Relevance 1.44 Pain Relevance 0
It was suggested, nearly a decade ago, that cholesterol inhibition could inhibit tumour cell growth and possibly prevent carcinogenesis [134].
Negative_regulation (inhibition) of cholesterol associated with cancer
12) Confidence 0.01 Published 2005 Journal J Negat Results Biomed Section Body Doc Link PMC1079931 Disease Relevance 0.59 Pain Relevance 0.04
It was hypothesised that statins, by improving endothelium dependent vasodilation at the arteriolar and capillary level [79], by their proangiogenic response independent of cholesterol reduction [80], and by inhibition of MMP-9 secretion by peripheral monocytes [81], could be beneficial in reducing claudication in patients with peripheral arterial occlusive disease (PAOD).
Negative_regulation (reduction) of cholesterol in endothelium associated with peripheral arterial disease and increased venous pressure under development
13) Confidence 0.01 Published 2005 Journal J Negat Results Biomed Section Body Doc Link PMC1079931 Disease Relevance 1.19 Pain Relevance 0
However, in all these studies the decrease in total cholesterol, LDL and triglycerides was only modest, and a significant number of patients did not achieve their NCEP goals.
Negative_regulation (decrease) of cholesterol associated with disorder of lipid metabolism
14) Confidence 0.01 Published 2005 Journal J Negat Results Biomed Section Body Doc Link PMC1079931 Disease Relevance 1.38 Pain Relevance 0
Inclusion of CLAs in a hypercholesterolemic diet in rabbits led to a significant reduction in serum triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and cholesterol (CHO) levels.
Negative_regulation (reduction) of cholesterol
15) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663461 Disease Relevance 0.73 Pain Relevance 0.12
Laboratory analyses included determination of C-reactive protein, fibrinogen, D-dimer, HDL-cholesterol, LDL-cholesterol and triglycerides.
Negative_regulation (determination) of LDL-cholesterol
16) Confidence 0.00 Published 2000 Journal Eur. Heart J. Section Body Doc Link 10901512 Disease Relevance 0.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox